Cited by 273Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismAtherosclerosis and Cardiovascular Diseases

The DOI matches its Crossref record; 126 of the 129 references it cites were found in a registry or an index.

The Evolving Future of PCSK9 Inhibitors

Open access

Rosenson, Robert S., Hegele, Robert A., Fazio, Sergio, Cannon, Christopher P.·2018·Journal of the American College of Cardiology

DOI 10.1016/j.jacc.2018.04.054

Open this paper in CoChat — free account Open PDF

Abstract

Variants in proprotein convertase subtilisin/kexin type 9 (PCSK9) provide insights into mechanisms regulating low-density lipoprotein (LDL) levels. Human monoclonal antibodies that target PCSK9 lower LDL cholesterol (LDL-C) levels by 55% to 72% in different high-risk patient groups. Clinical trials with PCSK9 inhibitors have demonstrated reductions in atherosclerotic cardiovascular disease events, particularly in patients with recent acute coronary syndrome, multivessel coronary artery disease, or peripheral arterial disease. Commonly observed profound reductions in LDL-C to levels <25 mg/dl have been accompanied by even lower rates of atherosclerotic cardiovascular disease events, thus supporting the concept that there may be no lower limit for LDL-C. Aggressive LDL-C lowering with fully human PCSK9 monoclonal antibodies has been accompanied by a safety profile that has been very favorable. On the basis of clinical trial evidence, LDL lowering with PCSK9 inhibitors is recommended for high-risk patients with LDL-C levels ≥70 mg/dl on maximally tolerated oral therapies including statins and/or ezetimibe.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2018.04.054

Cites

126 of 126 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Self-citation
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citation
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Self-citation
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Untitled work
Willer (2013) · doi:10.1038/ng.2797 · Cited by 2,983
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
Nordestgaard, B. G., Chapman, M. J., Humphries, S. E., Ginsberg, H. N., Masana, L., Descamps, O. S., Wiklund, O., Hegele, R. A., Raal, F. J., Defesche, J. C., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht273 · Cited by 2,761
Self-citation
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Interpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy, S. M., Cleeman, J. I., Bairey Merz, C. N., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.07.001 · Cited by 1,550
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381
The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation
Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial
Nicholls, S. J., Puri, R., Anderson, T., Ballantyne, C. M., Cho, L., Kastelein, J. J. P., Koenig, W., Somaratne, R., Kassahun, H., Yang, J., et al. (2016) · JAMA · doi:10.1001/jama.2016.16951 · Cited by 1,178
American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease
Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094
Self-citation
Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society
Cuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R. A., Kuivenhoven, J. A., Nordestgaard, B. G., Descamps, O. S., Steinhagen-Thiessen, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu274 · Cited by 1,057
Self-citation
Effects of anacetrapib in patients with atherosclerotic vascular disease
The HPS3/TIMI55–REVEAL Collaborative Group (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706444 · Cited by 1,047
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Ray, K. K., Landmesser, U., Leiter, L. A., Kallend, D., Dufour, R., Karakas, M., Hall, T., Troquay, R. P. T., Turner, T., Visseren, F. L. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615758 · Cited by 992
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
Yusuf, S., Bosch, J., Dagenais, G., Zhu, J., Xavier, D., Liu, L., Pais, P., López-Jaramillo, P., Leiter, L. A., Dans, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1600176 · Cited by 848
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)
Bonaca, M. P., Nault, P., Giugliano, R. P., Keech, A. C., Pineda, A. L., Kanevsky, E., Kuder, J., Murphy, S. A., Jukema, J. W., Lewis, B. S., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032235 · Cited by 766
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
Raal, F. J., Stein, E. A., Dufour, R., Turner, T., Civeira, F., Burgess, L., Langslet, G., Scott, R., Olsson, A. G., Sullivan, D., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61399-4 · Cited by 756
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
Ference, B. A., Robinson, J. G., Brook, R. D., Catapano, A. L., Chapman, M. J., Neff, D. R., Voros, S., Giugliano, R. P., Davey Smith, G., Fazio, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604304 · Cited by 743
Self-citation
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
Raal, F. J., Honarpour, N., Blom, D. J., Hovingh, G. K., Xu, F., Scott, R. C., Wasserman, S. M., & Stein, E. A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61374-x · Cited by 741
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Blom, D. J., Hala, T., Bolognese, M., Lillestol, M. J., Toth, P. D., Burgess, L., Ceska, R., Roth, E., Koren, M. J., Ballantyne, C. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316222 · Cited by 720
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
Giugliano, R. P., Pedersen, T. R., Park, J.-G., De Ferrari, G. M., Gaciong, Z. A., Ceska, R., Toth, K., Gouni-Berthold, I., Lopez-Miranda, J., Schiele, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32290-0 · Cited by 682
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials
Swerdlow, D. I., Preiss, D., Kuchenbaecker, K. B., Holmes, M. V., Engmann, J. E. L., Shah, T., Sofat, R., Stender, S., Johnson, P. C. D., Scott, R. A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61183-1 · Cited by 680
Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
Stein, E. A., Mellis, S., Yancopoulos, G. D., Stahl, N., Logan, D., Smith, W. B., Lisbon, E., Gutierrez, M., Webb, C., Wu, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105803 · Cited by 664
Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction
Do, R., Stitziel, N. O., Won, H.-H., Jørgensen, A. B., Duga, S., Angelica Merlini, P., Kiezun, A., Farrall, M., Goel, A., Zuk, O., et al. (2015) · Nature · doi:10.1038/nature13917 · Cited by 650
Self-citation
Molecular Characterization of Loss-of-Function Mutations in PCSK9 and Identification of a Compound Heterozygote
Zhao, Z., Tuakli-Wosornu, Y., Lagace, T. A., Kinch, L. N., Grishin, N. V., Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/507488 · Cited by 642
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
Ridker, P. M., Revkin, J., Amarenco, P., Brunell, R., Curto, M., Civeira, F., Flather, M., Glynn, R. J., Gregoire, J., Jukema, J. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701488 · Cited by 624
Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype
Maxwell, K. N., & Breslow, J. L. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402133101 · Cited by 613
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
Sabatine, M. S., Leiter, L. A., Wiviott, S. D., Giugliano, R. P., Deedwania, P., De Ferrari, G. M., Murphy, S. A., Kuder, J. F., Gouni-Berthold, I., Lewis, B. S., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30313-3 · Cited by 603
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
Kastelein, J. J. P., Ginsberg, H. N., Langslet, G., Hovingh, G. K., Češka, R., Dufour, R., Blom, D. J., Civeira, F., Krempf, M., Lorenzato, C., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv370 · Cited by 545
Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance
Stroes, E., Colquhoun, D., Sullivan, D., Civeira, F., Rosenson, R. S., Watts, G. F., Bruckert, E., Cho, L., Dent, R., Knusel, B., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.019 · Cited by 526
Self-citation
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial
Nissen, S. E., Stroes, E., Dent-Acosta, R. E., Rosenson, R. S., Lehman, S. J., Sattar, N., Preiss, D., Bruckert, E., Ceška, R., Lepor, N., et al. (2016) · JAMA · doi:10.1001/jama.2016.3608 · Cited by 522
Self-citation
ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures
Anderson, J. L., Heidenreich, P. A., Barnett, P. G., Creager, M. A., Fonarow, G. C., Gibbons, R. J., Halperin, J. L., Hlatky, M. A., Jacobs, A. K., Mark, D. B., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000042 · Cited by 521
A Spectrum of PCSK9 Alleles Contributes to Plasma Levels of Low-Density Lipoprotein Cholesterol
Kotowski, I. K., Pertsemlidis, A., Luke, A., Cooper, R. S., Vega, G. L., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/500615 · Cited by 517
Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia
Raal, F. J., Scott, R. C., Somaratne, R. M., Bridges, I. M., Li, G., Wasserman, S. M., & Stein, E. A. (2012) · Circulation · doi:10.1161/circulationaha.112.144055 · Cited by 506
Cognitive function in a randomized trial of evolocumab
Giugliano, R. P., Mach, F., Zavitz, K., Kurtz, C., Im, K., Kanevsky, E., Schneider, J., Wang, H., Keech, A., Pedersen, T. R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701131 · Cited by 492
Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
Roth, E. M., McKenney, J. M., Hanotin, C., Asset, G., & Stein, E. A. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201832 · Cited by 462
2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
Lloyd-Jones, D. M., Morris, P. B., Ballantyne, C. M., Birtcher, K. K., Daly, D. D., DePalma, S. M., Minissian, M. B., Orringer, C. E., & Smith, S. C. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.519 · Cited by 459
Familial hypercholesterolaemia
Defesche, J. C., Gidding, S. S., Harada-Shiba, M., Hegele, R. A., Santos, R. D., & Wierzbicki, A. S. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.93 · Cited by 453
Self-citation
Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients: The GAUSS Randomized Trial
Sullivan, D., Olsson, A. G., Scott, R., Kim, J. B., Xue, A., Gebski, V., Wasserman, S. M., & Stein, E. A. (2012) · JAMA · doi:10.1001/jama.2012.25790 · Cited by 447
ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures
Anderson, J. L., Heidenreich, P. A., Barnett, P. G., Creager, M. A., Fonarow, G. C., Gibbons, R. J., Halperin, J. L., Hlatky, M. A., Jacobs, A. K., Mark, D. B., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.016 · Cited by 447
Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel
Santos, R. D., Gidding, S. S., Hegele, R. A., Cuchel, M., Barter, P. J., Watts, G. F., Baum, S. J., Catapano, A. L., Chapman, M. J., Defesche, J. C., et al. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30041-9 · Cited by 440
Self-citation
Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment
Maxwell, K. N., Fisher, E. A., & Breslow, J. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409736102 · Cited by 415
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
Cannon, C. P., Cariou, B., Blom, D. J., McKenney, J. M., Lorenzato, C., Pordy, R. C., Chaudhari, U., & Colhoun, H. M. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv028 · Cited by 404
Self-citation
Association Between Low-Density Lipoprotein Cholesterol–Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis
Lotta, L. A., Sharp, S. J., Burgess, S., Perry, J. R. B., Stewart, I. D., Willems, S. M., Luan, J., Ardanaz, E., Arriola, L., Balkau, B., et al. (2016) · JAMA · doi:10.1001/jama.2016.14568 · Cited by 394
Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
Kazi, D. S., Moran, A. E., Coxson, P. G., Penko, J., Ollendorf, D. A., Pearson, S. D., Tice, J. A., Guzman, D., & Bibbins-Domingo, K. (2016) · JAMA · doi:10.1001/jama.2016.11004 · Cited by 382
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
Schmidt, A. F., Swerdlow, D. I., Holmes, M. V., Patel, R. S., Fairhurst-Hunter, Z., Lyall, D. M., Hartwig, F. P., Horta, B. L., Hyppönen, E., Power, C., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30396-5 · Cited by 380
Lipid-reduction variability and antidrug-antibody formation with bococizumab
Ridker, P. M., Tardif, J.-C., Amarenco, P., Duggan, W., Glynn, R. J., Jukema, J. W., Kastelein, J. J. P., Kim, A. M., Koenig, W., Nissen, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614062 · Cited by 369
The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population
Hooper, A. J., Marais, A. D., Tanyanyiwa, D. M., & Burnett, J. R. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.08.039 · Cited by 367
Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis
Akioyamen, L. E., Genest, J. J., Shan, S., Reel, R. L., Albaum, J. M., Chu, A., & Tu, J. V. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-016461 · Cited by 366
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study
Kereiakes, D. J., Robinson, J. G., Cannon, C. P., Lorenzato, C., Pordy, R., Chaudhari, U., & Colhoun, H. M. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.03.004 · Cited by 349
Self-citation
A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree
Timms, K. M., Wagner, S., Samuels, M. E., Forbey, K. C., Goldfine, H., Jammulapati, S., Skolnick, M. H., Hopkins, P. N., Hunt, S. C., & Shattuck, D. (2004) · Human Genetics · doi:10.1007/s00439-003-1071-9 · Cited by 322
Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction
Serban, M.-C., Colantonio, L. D., Manthripragada, A. D., Monda, K. L., Bittner, V. A., Banach, M., Chen, L., Huang, L., Dent, R., Kent, S. T., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.12.036 · Cited by 318
Self-citation
PCSK9R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease
Benn, M., Nordestgaard, B. G., Grande, P., Schnohr, P., & Tybjærg-Hansen, A. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.044 · Cited by 317
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER
Sabatine, M. S., De Ferrari, G. M., Giugliano, R. P., Huber, K., Lewis, B. S., Ferreira, J., Kuder, J. F., Murphy, S. A., Wiviott, S. D., Kurtz, C. E., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034309 · Cited by 255
Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial
Roth, E. M., Taskinen, M., Ginsberg, H. N., Kastelein, J. J. P., Colhoun, H. M., Robinson, J. G., Merlet, L., Pordy, R. C., & Baccara‐Dinet, M. T. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.06.049 · Cited by 248
Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study
Raal, F. J., Hovingh, G. K., Blom, D. J., Santos, R. D., Harada‐Shiba, M., Bruckert, É., Couture, P., Soran, H., Watts, G. F., Kurtz, C. E., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30044-x · Cited by 223
Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically
Wang, J., Dron, J. S., Ban, M. R., Robinson, J. F., McIntyre, A. D., Alazzam, M., Zhao, P., Dilliott, A. A., Cao, H., Huff, M. W., et al. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308027 · Cited by 210
Self-citation
Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?
Giugliano, R. P., & Sabatine, M. S. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.05.001 · Cited by 200
Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial
Moriarty, P. M., Parhofer, K. G., Babirak, S. P., Cornier, M.-A., Duell, P. B., Hohenstein, B., Leebmann, J., Ramlow, W., Schettler, V. J. J., Simha, V., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw388 · Cited by 198
PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia
Moens, S. J. B., Neele, A. E., Kroon, J., van der Valk, F. M., den Bossche, J. V., Hoeksema, M. A., Hoogeveen, R. M., Schnitzler, J. G., Baccara‐Dinet, M. T., Manvelian, G. Z., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx002 · Cited by 198
Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab
Robinson, J. G., Rosenson, R. S., Farnier, M., Chaudhari, U., Sasiela, W. J., Merlet, L., Miller, K., & Kastelein, J. J. P. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.037 · Cited by 197
Self-citation
Optimizing cholesterol treatment in patients with muscle complaints
Rosenson, R. S., Baker, S., Banach, M., Borow, K. M., Braun, L. T., Bruckert, E., Brunham, L. R., Catapano, A. L., Elam, M. B., Mancini, G. B. J., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.752 · Cited by 193
Self-citation
Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial
Farnier, M., Jones, P. J. H., Severance, R., Averna, M. R., Steinhagen‐Thiessen, E., Colhoun, H. M., Du, Y. E., Hanotin, C., & Donahue, S. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.11.010 · Cited by 190
Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation
Fisher, T. S., Surdo, P. L., Pandit, S., Mattu, M., Santoro, J. C., Wisniewski, D., Cummings, R. T., Calzetta, A., Cubbon, R. M., Fischer, P. A., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701634200 · Cited by 181
Serum Proprotein Convertase Subtilisin/Kexin Type 9 and Cell Surface Low-Density Lipoprotein Receptor: Evidence for a Reciprocal Regulation
Tavori, H., Fan, D., Blakemore, J. L., Yancey, P. G., Ding, L., Linton, M. F., & Fazio, S. (2013) · Circulation · doi:10.1161/circulationaha.113.001592 · Cited by 178
Self-citation
Low LDL cholesterol,PCSK9 and HMGCR genetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study
Benn, M., Nordestgaard, B. G., Frikke-Schmidt, R., & Tybjærg-Hansen, A. (2017) · BMJ · doi:10.1136/bmj.j1648 · Cited by 178
A Third Major Locus for Autosomal Dominant Hypercholesterolemia Maps to 1p34.1-p32
Varret, M., Rabès, J., Saint-Jore, B., Cenarro, A., Marinoni, J., Civeira, F., Devillers, M., Krempf, M., Coulon, M., Thiart, R., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302370 · Cited by 174
Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial
Moriarty, P. M., Jacobson, T. A., Bruckert, E., Thompson, P. D., Guyton, J. R., Baccara-Dinet, M. T., & Gipe, D. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.09.007 · Cited by 154
Advances in lipid-lowering therapy through gene-silencing technologies
Nordestgaard, B. G., Nicholls, S. J., Langsted, A., Ray, K. K., & Tybjærg‐Hansen, A. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2018.3 · Cited by 148
In vivo evidence that furin from hepatocytes inactivates PCSK9
Essalmani, R., Susan-Resiga, D., Chamberland, A., Abifadel, M., Creemers, J. W., Boileau, C., Seidah, N. G., & Prat, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.192104 · Cited by 144
The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability
Rosenson, R. S., Miller, K., Bayliss, M. S., Sanchez, R. J., Baccara‐Dinet, M. T., Chibedi-De-Roche, D., Taylor, B. A., Khan, I., Manvelian, G. Z., White, M. K., et al. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6723-4 · Cited by 142
Self-citation
Calcium cages, acid baths and recycling receptors
Brown, M. S., Herz, J., & Goldstein, J. L. (1997) · Nature · doi:10.1038/41672 · Cited by 137
Genetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm
Harrison, S. C., Holmes, M. V., Burgess, S., Asselbergs, F. W., Jones, G. T., Baas, A. F., Hof, F. N. G. V. ’., de Bakker, P. I. W., Blankensteijn, J. D., Powell, J. T., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.4293 · Cited by 131
Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms
Tavori, H., Giunzioni, I., Predazzi, I. M., Plubell, D. L., Shivinsky, A., Miles, J., DeVay, R. M., Hong, L., Rashid, S., Linton, M. F., et al. (2016) · Cardiovascular Research · doi:10.1093/cvr/cvw053 · Cited by 117
Self-citation
Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody
Hopkins, P. N., Defesche, J. C., Fouchier, S. W., Bruckert, É., Luc, G., Cariou, B., Sjouke, B., Leren, T. P., Harada‐Shiba, M., Mabuchi, H., et al. (2015) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.115.001129 · Cited by 116
Statins and the risk of new-onset diabetes
Preiss, D., & Sattar, N. A. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834b4994 · Cited by 113
PCSK9 Association With Lipoprotein(a)
Tavori, H., Christian, D., Minnier, J., Plubell, D. L., Shapiro, M. D., Yeang, C., Giunzioni, I., Croyal, M., Duell, P. B., Lambert, G. C., et al. (2016) · Circulation Research · doi:10.1161/circresaha.116.308811 · Cited by 109
Self-citation
Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia
Pisciotta, L., Oliva, C. P., Cefalu, A. B., Noto, D., Bellocchio, A., Fresa, R., Cantàfora, A., Patel, D., Averna, M. R., Tarugi, P., et al. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.08.015 · Cited by 108
Self-Association of Human PCSK9 Correlates with Its LDLR-Degrading Activity
Fan, D., Yancey, P. G., Qiu, S., Ding, L., Weeber, E. J., Linton, M. F., & Fazio, S. (2008) · Biochemistry · doi:10.1021/bi7016359 · Cited by 106
Self-citation
Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin
Giugliano, R. P., KEECH, A. C., Murphy, S. A., Huber, K., Tokgozoglu, S. L., Lewis, B. S., Ferreira, J., Pineda, A. L., Somaratne, R. M., Sever, P., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.3944 · Cited by 105
Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab
Thedrez, A., Blom, D. J., Ramin-Mangata, S., Blanchard, V., Croyal, M., Chemello, K., Nativel, B., Pichelin, M., Cariou, B., Bourane, S., et al. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.310217 · Cited by 105
Can LDL cholesterol be too low? Possible risks of extremely low levels
OLSSON, A. G., Angelin, B., Assmann, G., Binder, C. J., Björkhem, I., Cedazo-Mı́nguez, Á., Cohen, J. C., von Eckardstein, A., Farinaro, E., Müller‐Wieland, D., et al. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12614 · Cited by 102
Self-citation
Continued Statin Prescriptions After Adverse Reactions and Patient Outcomes
Zhang, H., Plutzky, J., Shubina, M., & Turchin, A. (2017) · Annals of Internal Medicine · doi:10.7326/m16-0838 · Cited by 94
PCSK9 Loss-of-Function Variants, Low-Density Lipoprotein Cholesterol, and Risk of Coronary Heart Disease and Stroke: Data From 9 Studies of Blacks and Whites
Kent, S. T., Rosenson, R. S., Avery, C. L., Chen, Y.-D. I., Correa, A., Cummings, S. R., Cupples, L. A., Cushman, M., Evans, D. S., Gudnason, V., et al. (2017) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.116.001632 · Cited by 86
Self-citation
Effects of Evolocumab on Vitamin E and Steroid Hormone Levels
Blom, D. J., Djedjos, C. S., Monsalvo, M. L., Bridges, I. M., Wasserman, S. M., Scott, R. C., & Roth, E. M. (2015) · Circulation Research · doi:10.1161/circresaha.115.307071 · Cited by 85
Loss of Plasma Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) After Lipoprotein Apheresis
Tavori, H., Giunzioni, I., Linton, M. F., & Fazio, S. (2013) · Circulation Research · doi:10.1161/circresaha.113.302655 · Cited by 83
Self-citation
PCSK9 is phosphorylated by a Golgi casein kinase‐like kinase ex vivo and circulates as a phosphoprotein in humans
Dewpura, T., Raymond, A., Hamelin, J., Seidah, N. G., Mbikay, M., Chrétien, M., & Mayne, J. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06495.x · Cited by 77
A Direct Role for the Macrophage Low Density Lipoprotein Receptor in Atherosclerotic Lesion Formation
Linton, M. F., Babaev, V. R., Gleaves, L. A., & Fazio, S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.27.19204 · Cited by 77
Self-citation
Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke
Hopewell, J. C., Malik, R., Valdés‐Márquez, E., Worrall, B. B., & Collins, R. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx373 · Cited by 77
Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants
Dron, J. S., & Hegele, R. A. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000386 · Cited by 72 · cited 3×
“Several different mechanisms can reduce PCSK9 function, including enhanced degradation, reduced intracellular transport, altered autocatalytic cleavage, and reduced LDLR affinity (21).”
BackgroundInfluentialSelf-citation
Evidence for a third genetic locus causing familial hypercholesterolemia: a non-LDLR, non-APOB kindred
Haddad, L., Day, I. N. M., Hunt, S. C., Williams, R. R., Humphries, S. E., & Hopkins, P. N. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33515-x · Cited by 70
A Recycling Pathway for Resecretion of Internalized Apolipoprotein E in Liver Cells*
Swift, L., Farkas, M. H., Major, A., Valyi-Nagy, K., Linton, M., & Fazio, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100172200 · Cited by 69
Self-citation
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia
Kastelein, J. J. P., Hovingh, G. K., Langslet, G., Baccara‐Dinet, M. T., Gipe, D. A., Chaudhari, U., Zhao, J. M., Minini, P., & Farnier, M. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.12.004 · Cited by 66
Nonstatin Low-Density Lipoprotein–Lowering Therapy and Cardiovascular Risk Reduction—Statement From ATVB Council
Hegele, R. A., Gidding, S. S., Ginsberg, H. N., McPherson, R., Raal, F. J., Rader, D. J., Robinson, J. G., & Welty, F. K. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306442 · Cited by 63 · cited 1×
“This has recently been readopted in the 2017 ACC Consensus Pathway for use of nonstatin agents (89,90).”
MethodSelf-citation
A Randomized Study of the Relative Pharmacokinetics, Pharmacodynamics, and Safety of Alirocumab, a Fully Human Monoclonal Antibody to PCSK 9, After Single Subcutaneous Administration at Three Different Injection Sites in Healthy Subjects
Lunven, C., Paehler, T., Poitiers, F., Brunet, A., Rey, J., Hanotin, C., & Sasiela, W. J. (2014) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12093 · Cited by 61
Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia
Hovingh, G. K., Raal, F. J., Dent, R. E., Stefanutti, C., Descamps, O. S., Masana, L., Lira, A., Bridges, I. M., Coll, B., & SULLIVAN, D. R. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.09.003 · Cited by 61
Effect of proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) monoclonal antibodies on new‐onset diabetes mellitus and glucose metabolism: Asystematic review and meta‐analysis
Cao, Y., Liu, H., Dong, Q., Li, S., & Li, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13235 · Cited by 61
Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia
Defesche, J. C., Stefanutti, C., Langslet, G., Hopkins, P. N., Seiz, W., Baccara‐Dinet, M. T., Hamon, S., Banerjee, P., & Kastelein, J. J. P. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.08.016 · Cited by 52
Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
Shapiro, M. D., Miles, J., Tavori, H., & Fazio, S. (2017) · Annals of Internal Medicine · doi:10.7326/m17-2485 · Cited by 51
Self-citation
Loss of Macrophage Low-Density Lipoprotein Receptor–Related Protein 1 Confers Resistance to the Antiatherogenic Effects of Tumor Necrosis Factor-α Inhibition
Zhu, L., Giunzioni, I., Tavori, H., Covarrubias, R., Ding, L., Zhang, Y., Ormseth, M., Major, A. S., Stafford, J. M., Linton, M. F., et al. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.307736 · Cited by 46
Self-citation
Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables
Filippatos, T. D., Kei, A. A., Rizos, C. V., & Elisaf, M. (2017) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248417724868 · Cited by 46
PCSK9 Variants, Low-Density Lipoprotein Cholesterol, and Neurocognitive Impairment: Reasons for Geographic and Racial Differences in Stroke Study (REGARDS)
Mefford, M. T., Rosenson, R. S., Cushman, M., Farkouh, M. E., McClure, L. A., Wadley, V. G., Irvin, M. R., Bittner, V., Safford, M. M., Somaratne, R., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.029785 · Cited by 44
Self-citation
New developments in proprotein convertase subtilisin–kexin 9's biology and clinical implications
Seidah, N. G. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000295 · Cited by 43
Characterization of the First PCSK9 Gain of Function Homozygote
Alves, A. C., Etxebarria, A., Medeiros, A. M., Benito‐Vicente, A., Thedrez, A., Passard, M., Croyal, M., Martı́n, C., Lambert, G. C., & Bourbon, M. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.08.871 · Cited by 34
The ever-expanding saga of the proprotein convertases and their roles in body homeostasis: emphasis on novel proprotein convertase subtilisin kexin number 9 functions and regulation
Seidah, N. G., Chrétien, M., & Mbikay, M. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000484 · Cited by 31
Normalization of Low-Density Lipoprotein Receptor Expression in Receptor Defective Homozygous Familial Hypercholesterolemia by Inhibition of PCSK9 With Alirocumab
Lambert, G. C., Chatelais, M., Petrides, F., Passard, M., Thedrez, A., Rye, K., Schwahn, U., Gusarova, V., Blom, D. J., Sasiela, W. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.07.995 · Cited by 30
Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts
Nguyen, M.-A., Kosenko, T., & Lagace, T. A. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m044156 · Cited by 30
Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab
Desai, N. R., Giugliano, R. P., Wasserman, S. M., Gibbs, J. P., Liu, T., Scott, R. C., & Sabatine, M. S. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2016.5395 · Cited by 30
Mutation S462P in the PCSK9 gene reduces secretion of mutant PCSK9 without affecting the autocatalytic cleavage
Cameron, J., Holla, Ø. L., Laerdahl, J. K., Kulseth, M. A., Berge, K. E., & Leren, T. P. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.10.007 · Cited by 29
Application of the Statin-Associated Muscle Symptoms-Clinical Index to a Randomized Trial on Statin Myopathy
Taylor, B. A., Sanchez, R. J., Jacobson, T. A., Chibedi-De-Roche, D., Manvelian, G. Z., Baccara‐Dinet, M. T., Khan, I., & Rosenson, R. S. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.767 · Cited by 29
Self-citation
Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia—Brief Report
Thedrez, A., Sjouke, B., Passard, M., Prampart, S., Guédon, A. F., Croyal, M., Dallinga‐Thie, G. M., Peter, J., Blom, D. J., Ciccarese, M., et al. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307493 · Cited by 24
Effect of intensive LDL cholesterol lowering with PCSK9 monoclonal antibodies on tendon xanthoma regression in familial hypercholesterolemia
Bea, A. M., Pérez‐Calahorra, S., Marco-Benedí, V., Lamíquiz-Moneo, I., Jarauta, E., Mateo‐Gállego, R., & Civeira, F. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.06.009 · Cited by 20
Alternative Treatment Regimens With the PCSK9 Inhibitors Alirocumab and Evolocumab: A Pharmacokinetic and Pharmacodynamic Modeling Approach
Scherer, N., Dings, C., Böhm, M., Laufs, U., & Lehr, T. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.866 · Cited by 15
Trial designs for statin muscle intolerance
Rosenson, R. S. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000454 · Cited by 6
Self-citation
Abstract 15100: Reduction in Total Cardiovascular Events With the PCSK9 Inhibitor Evolocumab in Patients With Cardiovascular Disease in the FOURIER Trial
Murphy, S. A., Pedersen, T. R., Gaciong, Z. A., Češka, R., Владиславович, Е. М., Connolly, D. L., Крайдашенко, О. В., Jukema, J. W., Tóth, K., Tikkanen, M. J., et al. (2017) · Circulation · Cited by 4

Flagged first, then by citations

3 of the 129 references couldn’t be matched to a known paper.

Research works printed but not linked: 4

Kastelein, 2015, ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia, Eur Heart J, 36, 2996
Hopkins, 2015, Characterization of autosomal dominant hypercholesterolemia caused by PCSK9 gain of function mutations and its specific treatment with alirocumab, a PCSK9 monoclonal antibody, Circ Cardiovasc Genet, 8, 823, 10.1161/CIRCGENETICS.115.001129 · DOI
Institute for Clinical and Economic Review posts updated economic analyses for PCSK9 inhibitor evolocumab, finds less favorable cost-effectiveness [press release]. Boston, MA: ICER; September 11, 2017. Available at: https://icer-review.org/announcements/pcsk9-neu/. Accessed April 4, 2018.
Institute for Clinical and Economic Review updates value-based price benchmark for alirocumab, a PCSK9 inhibitor for treatment of high cholesterol [press release]. Boston, MA: ICER; March 10, 2018. Available at: https://icer-review.org/announcements/alirocumab-prelim-evidence-update/. Accessed April 4, 2018.

Sorted by citations

Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities
Bäck, M., Yurdagul, A., Tabas, I., Öörni, K., & Kovanen, P. T. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0169-2 · Cited by 1,341
Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials
Guedeney, P., Giustino, G., Sorrentino, S., Claessen, B. E., Camaj, A., Kalkman, D. N., Vogel, B., Sartori, S., De Rosa, S., Baber, U., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehz430 · Cited by 208
Self-citation
Coronary Atherosclerotic Plaque Regression
Dawson, L. P., Lum, M., Nerlekar, N., Nicholls, S. J., & Layland, J. J. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.10.035 · Cited by 209
Lipid-Lowering Agents: Targets Beyond PCSK9
Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313171 · Cited by 171
Self-citation
Familial Hypercholesterolemia: The Most Frequent Cholesterol Metabolism Disorder Caused Disease
Benito‐Vicente, A., Uribe, K. B., Jebari‐Benslaiman, S., Galicia-García, U., Ostolaza, H., & Martín, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113426 · Cited by 151

See all 273

Authors: Rosenson, R. S., Hegele, R. A., Fazio, S., & Cannon, C. P.
Affiliations: Mount Sinai Hospital (US)
Western University (CA)
Oregon Health & Science University (US)
Brigham and Women's Hospital (US)
Corresponding author: Rosenson, Robert S.
ORCID: Rosenson, Robert S.
Hegele, Robert A.
Fazio, Sergio
Cannon, Christopher P.
Venue: Journal of the American College of Cardiology
Publisher: Elsevier BV
Published: 2018-07
Volume: 72
Issue: 3
Pages: 314-329
ISSN: 0735-1097 (ISSN-L)
DOI: 10.1016/j.jacc.2018.04.054
OpenAlex: W2848978533
Cited by: 264
References: 129
Citations by year: 2026: 18 · 2025: 39 · 2024: 34 · 2023: 47 · 2022: 31 · 2021: 35 · 2020: 27 · 2019: 26 · 2018: 7
FWCI: 5.28
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 381 d)
Locations: Journal of the American College of Cardiology (publishedVersion)
PubMed (publishedVersion)
Funders: Amgen
Pfizer
AstraZeneca
Sanofi
American College of Cardiology Foundation
Regeneron Pharmaceuticals
Kowa Company
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
Keywords: PCSK9 inhibitors, PCSK9, LDL cholesterol lowering, monoclonal antibodies, atherosclerotic cardiovascular disease, acute coronary syndrome, multivessel coronary artery disease, peripheral arterial disease, hypercholesterolemia
MeSH terms: Proprotein Convertase 9, PCSK9 Inhibitors, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Clinical Trials as Topic, Humans, Hypercholesterolemia, Cholesterol, LDL, Treatment Outcome, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Evolving Future of PCSK9 Inhibitors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks